EXHIBIT 10.10 COLLABORATION AGREEMENT THIS COLLABORATION AGREEMENT (the "Agreement") is entered into as of May 2, 1998 (the "Effective Date"), by and between CALIPER TECHNOLOGIES CORP., a corporation organized under the laws of the State of Delaware...

1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

EXHIBIT 10.10

COLLABORATION AGREEMENT

THIS COLLABORATION AGREEMENT (the "Agreement") is entered into as of
May 2, 1998 (the "Effective Date"), by and between CALIPER TECHNOLOGIES CORP., a
corporation organized under the laws of the State of Delaware ("Caliper"), and
HEWLETT-PACKARD Company, a corporation organized under the laws of the State of
California, acting through its Chemical Analysis Group ("HP").

RECITALS

A. Caliper is a company engaged in the development of new technology
and products in microfluidics and related areas that can be used to improve the
chemical and biochemical analysis activities of pharmaceutical and other types
of companies.

B. HP is a multinational company which through its Chemical Analysis
Group is a leading worldwide developer and supplier of instrumentation, supplies
and services to customers in pharmaceutical and other industries.

C. HP and Caliper wish to form a collaboration to develop and
commercialize products based on Caliper's microfluidics technology and HP's
instrumentation technology for use in the field of chemical and biochemical
research and analysis, and to provide a business infrastructure for the
manufacture, sale, distribution and support of those products.

THE PARTIES THEREFORE AGREE:

1. DEFINITIONS

Each of the capitalized terms in this Agreement shall have the
meaning as defined below. Terms defined in singular form shall include the
plural form and vice versa.

"AFFILIATES" shall mean any company or entity controlled by,
controlling, or under common control with a party hereto and shall include
without limitation any company more than fifty percent (50%) of whose voting
stock or participating profit interest is owned or controlled, directly or
indirectly, by a party, and any company which owns or controls, directly or
indirectly, more than fifty percent (50%) of the voting stock of a party.

"AFM" shall mean HP's Accounting and Finance Manual which is intended
to provide financial policy guidelines and specific instructions concerning HP's
accounting and reporting processes in effect as of the Effective Date and as
updated from time to time provided Caliper has been furnished with such updates
and afforded a reasonable opportunity to object to its use

with this Agreement. Where applicable and mutually agreed, the AFM will be
extended to provide guidelines and specific instructions for the collaboration.

"ALLOWABLE EXPENSE" shall mean those expenses incurred by a party
consisting of [ * ], and any other amounts on which the parties agree from time
to time to the extent such amounts are not included in Cost of Sales.

"APPLICATION" means a particular task, experiment or biochemical or
chemical manipulation, or series thereof, that a potential user of a
Collaboration Product wishes or needs to perform.

"APPLICATION KIT" shall mean a set of Components that are sold
together as a package to System users for purposes of performing a specific
Application, including without limitation, LabChips, Reagents and the
Application-specific portion of System Software.

"BUSINESS PLAN" shall mean the Collaboration business plan
established by the parties pursuant to Article 3, in accordance with the HP Ten
Step Planning Process.

"CALIPER DEVELOPMENT EXPENSES" shall mean [ * ] activities under the
Product Plan for Collaboration Products calculated as [ * ]. All these expenses
shall be applicable to such activities, beginning from the time a Component is
placed on the Development Plan.

"CALIPER KNOW-HOW" shall mean all scientific, technical and
engineering information which Caliper owns or controls or to which Caliper has a
license including the right of sublicense as of the Effective Date or during the
term of the Collaboration, which Caliper uses reasonable efforts to protect as a
trade secret, and which is not publicly accessible in an issued patent or
otherwise.

"CALIPER OPERATING EXPENSES" shall mean all monies applied by Caliper
and its Third Party collaborators to [ * ] relating to Lab-on-a-Chip Technology
or systems utilizing Lab-on-a-Chip Technology, to the extent that such [ * ] are
relevant to [ * ] as reasonably determined by Caliper, except to the extent that
[ * ], and excluding any amounts provided to Caliper by HP under Section 7.2,
consisting of but not limited to, [ * ].

"CALIPER PATENTS" shall mean (i) all patents, including, without
limitation, any substitutions, extensions, reissues, renewals, supplementary
protection certificates and inventors' certificates, which have not been held
invalid or unenforceable by a non-appealable or non-appealed decision of a court
of competent jurisdiction, and (ii) all patent applications filed in any
jurisdiction, including, without limitation, any provisionals, divisionals,
continuations, continuations-in-part, which in each case Caliper owns, controls
or has a license to (with the right to sublicense) as of the Effective Date or
during the term of the Collaboration.

"CALIPER TECHNOLOGY" shall mean Caliper Patents and Caliper Know-How
relating to Lab-on-a-Chip Technology. Rights to Caliper Technology under this
Agreement shall be subject to any restrictions or obligations (including payment
obligations) contained in agreements between Caliper and a Third Party.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

2
3

"CLASS A PRODUCTS" shall mean LabChips; Reagents [ * ].

"CLASS B PRODUCTS" shall mean Instruments [ * ].

"CLASS C PRODUCTS" shall mean general purpose products that are sold
separately by HP or Third Parties for end use separate from LabChip-based
Systems. This is in contrast to components or devices embedded in Instruments.
Examples of Class C Products include [ * ].

"COLLABORATION" shall mean all activities relating to Collaboration
Products conducted by the parties pursuant to this Agreement.

"COLLABORATION MANAGERS" shall mean the persons assigned by each
party to the management of the Collaboration as further described in Section
3.2(b) below.

"COLLABORATION PRODUCTS" shall mean the Systems in the Field of
Interest that the parties put on a Product Plan and all Components that make up
such Systems. "Collaboration Products" shall include HP Collaboration Products
(as defined below). For purposes of Article 10 only, "Collaboration Products"
shall only include such [ * ] during the Collaboration.

"COMPONENT" shall mean one of the elements of a complete System,
including but not limited to, the LabChip, the Instrument, the System Software
or a Reagent.

"CONFIDENTIAL INFORMATION" shall mean any trade secret information
disclosed by one party to the other in connection with activities under this
Agreement, including but not limited to scientific, technical and engineering
information, reports exchanged between the parties, marketing and other business
plans, information relating to a party's products, sales, financial and
corporate affairs, suppliers, customers, employees, or investors, and other
comparable information; provided, that information will be "Confidential
Information" only if it is marked as confidential at the time of disclosure or,
if the material is not in written form (e.g. orally disclosed), it is treated as
confidential at the time of disclosure and is designated as confidential in a
written memorandum sent to the recipient within thirty days of disclosure,
summarizing the confidential information sufficiently for identification.

"COST OF SALES" shall mean [ * ]. Notwithstanding the AFM, as used in
this Agreement the term Cost of Sales does not include [ * ].

"DATA ACQUISITION SOFTWARE" shall mean software that sends data
measured by the Instrument to a file, database or memory. Such data set is used
for generating the measurement information from an Application or for displaying
status information of the Application in the user interface of the System
Software or the Instrument.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

3
4

"DATA INTERPRETATION SOFTWARE" shall mean software that evaluates
data measured by the Instrument according to algorithms with Distinct
Functionality for a particular Application. Parameters for the Data
Interpretation Software are defined in the Experimental Method and are entered
through the user interface component of the Data Interpretation Software module
of the System Software. For example, Data Interpretation Software could use a
pattern recognition algorithm to interpret the data generated by an Application.

"DEVELOPMENT PLAN" shall mean the component of the Product Plan that
sets forth a detailed plan for the development of a particular Collaboration
Product as described in Section 3.2(b) below.

"DISTINCT FUNCTIONALITY" shall mean functionality of a Component or
System that [ * ]. For example, a [ * ] would not have Distinct Functionality.

"ENGINEERING RESPONSIBILITY" shall mean ultimate responsibility for
deciding upon final specifications and for developing the manufacturing
processes for meeting such specifications.

"EXECUTIVE SPONSOR" shall mean the persons assigned by each party to
the oversight of the Collaboration between the parties created by this
Agreement, and responsible for dispute resolution as further described in
Section 3.2(a) below.

"EXPERIMENTAL METHOD" shall mean a set of data or instructions, not
necessarily in the form of software, used to control the Components of a System,
which Components may be common to multiple Applications, for performance of a
particular Application. For a particular Application, for example, the
Experimental Method performs control of Instruments (e.g., control chip voltages
and detector setpoints) and defines the particular data interpretation
algorithm, information presentation or information management routines in the
System Software.

"FIRMWARE" shall mean software that physically resides in the
Instrument. Firmware controls the hardware functions of the Instrument,
communicates with other functional modules in the System and executes the
Instrument control part of the Experimental Method for a particular Application.

"FDA" shall mean the United States Food and Drug Administration, and
any successor thereto.

"FIELD OF INTEREST" shall have the meaning provided in Section 2.2
below.

"GROSS MARGIN" shall mean [ * ].

"GROSS REVENUES" shall mean [ * ]. Handling of bundling will be set
forth in Article 7.

"HP COLLABORATION PRODUCT" shall have the meaning set forth in
Section 4.2(d).

"HP KNOW-HOW" shall mean all scientific, technical and engineering
information which HP owns or controls or to which HP has a license including the
right of sublicense as of the

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

4
5

Effective Date or during the term of the Collaboration, which HP uses reasonable
efforts to protect as a trade secret, which HP elects to incorporate into or use
in the design, development or manufacturing of Collaboration Products during the
course of the Collaboration, and which is not publicly accessible in an issued
patent or otherwise.

"HP OPERATING EXPENSES" shall mean the expenses incurred by HP [ * ],
consisting of but not limited to, [ * ].

"HP PATENTS" shall mean (i) all patents, including, without
limitation, any substitutions, extensions, reissues, renewals, supplementary
protection certificates and inventors' certificates, which have not been held
invalid or unenforceable by a non-appealable or non-appealed decision of a court
of competent jurisdiction, and (ii) all patent applications filed in any
jurisdiction, including, without limitation, any provisionals, divisionals,
continuations, continuations-in-part, which in each case HP owns, controls or
has a license to (with the right to sublicense) as of the Effective Date or
during the term of the Collaboration.

"HP TECHNOLOGY" shall mean HP Patents and HP Know-How. Rights to HP
Technology under this Agreement shall be subject to any restrictions or
obligations (including payment obligations) contained in Third Party agreements.

"INFORMATION MANAGEMENT SOFTWARE" shall mean software that manages
data, including the Experimental Method-, measured- or results data for a
particular Application. The functions of such software include, but are not
limited to, archiving, retrieving, searching for or mailing information. Such
tasks are initiated through a user interface component of this functional module
of the System Software.

"INFORMATION PRESENTATION SOFTWARE" shall mean software that
visualizes or saves evaluated data through various media (e.g., display, disc,
printer). Other software tools may also be used for reporting or accessing the
results (e.g., standard office software packages like MS WinWord(TM),
Browsers(TM)). Specific parameters for Information Presentation Software are
defined in the Experimental Method and are entered through the user interface
component of the Information Presentation Software functional module.

"INSTRUMENT" shall mean all hardware in a System, excluding [ * ].

"INSTRUMENT CONTROL SOFTWARE" shall mean software that communicates
data to and from the Instrument through the appropriate instrument driver and
physical link driver, including but not limited to, Scripts. Such data is either
entered through the user interface of the System or System Software or received
and saved in the Experimental Method data file or database. Data received can
also be shown by other means, e.g., a display on the Instrument.

"LABCHIP" shall mean a chip, based on Caliper Technology, which is
designed to perform an Application or portion thereof when used in a System. As
of the Effective Date, such chips typically consist of [ * ].

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

5
6

"LAB-ON-A-CHIP TECHNOLOGY" shall mean microfluidic systems, methods,
devices, and structures which have microfluidic processing elements that have
[ * ] as further defined in Exhibit A to this Agreement.

"MANUFACTURING PLAN" shall mean the component of the Product Plan
that sets forth a detailed plan for the manufacturing of a Collaboration Product
as set forth in Section 5.2(a) below.

"MARKETING PLAN" shall mean the component of the Product Plan that
sets forth a detailed plan for the marketing, distribution and support of a
Collaboration Product.

"NET REVENUES" shall mean [ * ].

"NEW PRODUCT" shall mean a Component or a System in the Field of
Interest, having Distinct Functionality compared to a Collaboration Product,
that is developed independently by either party after the termination or
expiration of the Collaboration.

"NON-COLLABORATION PRODUCT" shall mean any product that includes HP
Technology or Caliper Technology and does not fall within the definition of a
Collaboration Product.

"OEM" stands for original equipment manufacturer.

"PATENT COSTS" shall mean the fees and expenses paid to outside
counsel and other Third Parties, direct costs of in-house counsel, and filing
and maintenance fees and expenses, incurred in connection with the establishment
and maintenance of rights under patents, including costs of patent interference,
opposition, reissue, reexamination or other proceedings before the USPTO or
other patent offices. In-house counsel costs shall be determined on the basis of
time actually spent on patents applicable to Collaboration Products.

"PMA" shall mean a Premarket Approval Application filed with the FDA,
or foreign equivalent, as applicable.

"PRODUCT PROGRAM MANAGER" shall mean the persons assigned by each
party to the management of the development of a Collaboration Product as further
described in Section 3.2(c).

"PRODUCT PLAN" shall mean the plan established by the parties
pursuant to Article 3 of this Agreement. The Product Plan shall include the
following components for each Collaboration Product: the Development Plan, the
Manufacturing Plan and the Marketing Plan, in accordance with CAG's Project
Lifecycle.

"REAGENT" shall mean a chemical or biochemical substance to be used
with a LabChip for a particular Application.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

6
7

"SCRIPT" shall mean a set of instructions (typically, a software
file) that is sent to the Instrument to control the LabChip environment and
fluidic manipulations inside the LabChip, including but not limited to [ * ].
Typically there will be a [ * ].

"STANDARD COST" shall mean [ * ]. Such costs include but are not
limited to [ * ]. Overhead Expenses include [ * ]. All of these Overhead Expense
items consist of, but are not limited to, [ * ]. These Standard Costs for a
Collaboration Product are [ * ].

"SYSTEM" shall mean a complete set of chips, hardware, software and
reagents that makes use of Caliper Technology to perform a single Application,
excluding Class C Products.

"SYSTEM SOFTWARE" shall mean all software used in a System. System
Software defines and executes the Experimental Method for a particular
Application and includes, but is not limited to, Instrument Control Software,
Data Acquisition Software, Data Interpretation Software, Information
Presentation Software, Information Management Software and Firmware.

"THIRD PARTY" shall mean any individual or entity other than Caliper,
HP or Affiliates of either.

"TRANSFER PRICE" shall mean the price HP pays to Caliper for any
Collaboration Products that are manufactured by Caliper and sold to HP. This
price is equal to [ * ].

"U.S. GAAP" shall mean `Generally Accepted Accounting Principles' and
refers to accounting policies and procedures that are widely used in the U.S.

"VAR" stands for value added reseller.

2. LICENSES AND EXCLUSIVITY

2.1 LICENSES TO HP

(a) COLLABORATION PRODUCTS. Subject to the terms and conditions
of this Agreement, Caliper hereby grants to HP a worldwide license, co-exclusive
with Caliper, under the Caliper Technology to develop, manufacture for
Commercial Sale, market, distribute, sell and support Collaboration Products.
Notwithstanding, HP, except as provided in Sections 4.2(d) and 5.1(c), is not
granted a license to develop or manufacture LabChips. Caliper represents that it
has not heretofore granted any licenses under the Caliper Technology that would
grant the licensee the right to develop, manufacture for Commercial Sale,
market, distribute, sell or support Collaboration Products, except as heretofore
disclosed.

(b) SUBLICENSING. HP may sublicense the manufacturing rights
granted to it under subsection 2.1(a) under the procedures set forth in Section
5.1(b), and HP may sublicense the distribution rights as provided in Section 6.3
of this Agreement. No other license rights under subsection 2.1(a) may be
sublicensed or transferred except by mutual written agreement.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

7
8

(d) RESTRICTIONS ON USE OF CALIPER KNOW-HOW. HP acknowledges that
the use of Caliper Know-How under the licenses to HP set forth above in this
Section 2.1 is limited to use of such Caliper Know-How solely in the Field of
Interest. HP agrees to use reasonable business efforts to avoid use of the
Caliper Know-How outside the Field of Interest by HP, its Affiliates or
sublicensees, and to avoid disclosure of such Caliper Know-How by HP or its
Affiliates and sublicensees to any party who does not have a need to know such
Caliper Know-How for purposes of the Collaboration. HP agrees that if it
discovers at any time that Caliper Know-How is being used by any such person
outside the Field of Interest, it will promptly disclose such use to Caliper and
the parties will confer in order to determine a reasonable and effective means
of addressing such unauthorized use.

(e) SOFTWARE.

(i) Subject to the terms and conditions of this Agreement,
Caliper hereby grants HP a non-exclusive, non-transferable license under Caliper
Technology and any applicable copyright to reproduce, create derivative works,
publicly distribute, publicly perform and publicly display System Software (both
source and object code) for use in Collaboration Products; provided, that HP may
not disclose any source code provided by Caliper to Third Parties except to
contractors under duty of confidentiality to HP. Caliper will provide updates to
source and object code and available documentation from time to time upon
request of HP. Under this license HP may sublicense manufacturing and
distribution rights to the same extent as HP may sublicense other Caliper
Technology under section 2.1(b).

(ii) Caliper hereby grants HP a royalty-free, non-exclusive
license including the right of sublicense under Caliper Technology and any
applicable copyright to reproduce, create derivative works, publicly distribute,
publicly perform and publicly display any improvements to software originally
created by HP (both source and object code) for use in all fields. Caliper will
provide updates to any such improvements from time to time upon request of HP.

(f) RETAINED RIGHTS. All rights in Caliper Technology not
expressly granted to HP in this Agreement are retained exclusively by Caliper.

2.2 FIELD OF INTEREST. The term "Field of Interest" shall mean
Commercial Sale of Limited Through-Put products for research, development,
analytical or manufacturing Applications, including [ * ] but not other
Diagnostic Products, and excluding [ * ], which products are designed (i) to
introduce and prepare chemical, biochemical and biological samples, (ii) to
perform assays, synthesis and other reactions, or (iii) to perform physical
separations and detection.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

8
9

(a) THROUGH-PUT LIMITS.

(i) "Limited Through-Put" as used herein shall mean sample
throughput per System not exceeding the volume limits set forth below based on
operation of the product for [ * ]:

Years [ * ] [ * ]

[ * ].

(ii) The parties intend to develop Collaboration Products
that will have a leading edge relative to the competition. The parties will
strive to maintain a leading edge by proactively reviewing the state of
competitors' development and commercial efforts, to the extent information is
available. If at any time the through-put limits set forth above would prevent a
Collaboration Product from having a leading edge with regard to a particular
Application over competing products being actively developed or marketed for
Commercial Sale by Third Parties, then the parties will review such limits and
reasonably discuss potential changes in good faith with regard to the particular
Application, subject to any existing Third Party commitments.

(iii) The parties acknowledge that customers may purchase
multiple Systems for certain Applications in order to increase their through-put
capacity, and that it may be beneficial to the Collaboration for HP to assist
such customers in these efforts. Accordingly, HP is authorized to [ * ] .
Notwithstanding the foregoing, the parties agree that all Systems that are
developed and commercialized under this Collaboration shall be [ * ].

(b) "COMMERCIAL SALE" as used herein shall mean sale of
Collaboration Products in volumes of [ * ]. A proposed Collaboration Product
will be considered to be for "Commercial Sale" provided there is a reasonable
projection in the Product Plan that it will be sold in such quantity [ * ]. The
parties recognize that sales volume projections are inexact. HP will retain
rights to Instruments, System Software and related Systems that do not actually
meet these sales projections, provided the volume estimates were reasonable
throughout the development process for such Instruments, System Software and
related Systems. "Commercial Sale" does not include the use of Caliper
Technology to commercialize [ * ], but Collaboration Products offered for
Commercial Sale may be used by customers for such purposes. "Commercial Sale"
does not include the use of Caliper Technology to provide [ * ].

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

9
10
(i) The parties acknowledge that HP may introduce
Instruments to selected customers on a limited basis [ * ] prior to general
commercial introduction, for the purpose of obtaining customer feedback prior to
introduction, and that such beta testing shall not be considered general
commercial introduction.

(ii) Caliper may, acting independently or in collaboration
with others, develop, make and distribute to Third Parties any System. However,
Caliper may only do this if Caliper limits actual sales of Systems to [ * ].
Systems must have Distinct Functionality to be counted separately under this
Subsection. Caliper may sell any number of LabChips, Reagents and other
consumables for use on such Systems. Caliper will label such Instruments "not
for resale," [ * ].

(c) "DIAGNOSTIC PRODUCTS" as used herein shall mean products that
are subject to regulatory approval requirements under applicable law,
regulations or policies of regulatory agencies (i.e., PMA or 510(k), or foreign
equivalent) and are useful for chemical or biochemical analysis of human samples
in a health care setting, such as a reference laboratory, hospital laboratory,
hospital, clinic, doctor's office or at home, and veterinary products utilizing
similar technology to the above products. HP will not be prohibited from selling
Collaboration Products designed for research, development, analytical or
manufacturing use to such customers, provided all products are labeled in
accordance with Section 6.4. Caliper will not be prohibited from introducing
products designed for diagnostic use by such customers while Caliper is in the
course of pursuing FDA approval on such a product, or from transferring such
rights to any Third Party.

2.3 EXCLUSIVITY

(a) During the Collaboration, the relationship will be mutually
exclusive with respect to the application of Lab-on-a-Chip Technology to the
Field of Interest, meaning that [*].

(b) Caliper acknowledges that HP has been and will continue to be
engaged in [ * ], and that this Section does not prohibit HP from (i) pursuing
its internally developed [ * ], outside the Field of Interest, such as
diagnostics; or (ii) working with any Third Party [ * ]. To the extent that
these activities constitute application of Lab-on-a-Chip Technology to the Field
of Interest, they will be subject to the provisions of Section 2.3(a). Caliper
will not be free to use HP [ * ] disclosed under confidentiality for any purpose
outside the Collaboration (except as otherwise expressly licensed under this
Agreement), and HP will not be free to use Caliper [ * ] disclosed under
confidentiality for any purpose outside the Collaboration (except as otherwise
expressly licensed under this Agreement). HP and Caliper will use all reasonable
business efforts to manage their collaborative and independent activities so as
to xxxxxx an environment of open communication for collaborative purposes while
protecting the integrity of independent activities.

10
11

2.4 LICENSES TO CALIPER

(a) HP Know-How License. Subject to the terms and conditions of
this Agreement, HP hereby grants to Caliper a worldwide, fully-paid,
non-exclusive, license, with the right to grant sub-licenses, to develop, make,
use, import and sell all Non-Collaboration Products that make use of Caliper
Technology for use in all fields during and after the term of the Agreement,
using all HP Know-How, excluding any HP Confidential Information directed to
HP's [ * ]. Upon request from Caliper, HP will use reasonable business efforts
to provide such HP Know-How or to allow Caliper access to such HP Know-How in a
reasonable format.

(b) HP Patent License. HP will notify Caliper in writing at the
time HP proposes to incorporate subject matter claimed in an HP Patent that was
first applied for prior to or during the Collaboration into a Collaboration
Product, or to practice such an HP Patent in the development or manufacture of a
Collaboration Product, or at the time HP learns that such an HP Patent covers a
Collaboration Product. HP hereby grants Caliper a [ * ] license to any such HP
Patent (except to the extent such HP Patent covers HP's [ * ]) subject to
agreement of the parties on [ * ]. Such license includes:

(i) a license under such HP Patent to develop
Non-Collaboration Products that include Caliper Technology for use in all fields
during and after the term of the Agreement; and

(ii) a license under such HP Patent including the right of
sublicense to make, have made, use, sell, offer for sale and import
Non-Collaboration Products that include Caliper Technology for use in all fields
during and after the term of the Agreement.

(c) HP SOFTWARE LICENSE. HP hereby grants Caliper a license under
HP Technology and any applicable copyright to any System Software (both source
and object code) subject to agreement of the parties on [ * ]; provided, that
Caliper may not disclose the source code to Third Parties except to contractors
under duty of confidentiality to Caliper. HP will provide updates to source and
object code and available documentation from time to time upon request of
Caliper. Such license includes:

(i) a non-exclusive, worldwide license under such System
Software to create derivative works for use in Non-Collaboration Products that
make use of Caliper Technology for use in all fields during and after the term
of the Agreement; and

(ii) a non-exclusive, worldwide license including the right
of sublicense under such System Software to reproduce, publicly distribute,
publicly perform and publicly display Non-Collaboration Products that make use
of Caliper Technology for use in all fields during and after the term of the
Agreement.

(d) SOFTWARE IMPROVEMENTS. HP hereby grants Caliper a
royalty-free, non-exclusive license including the right of sublicense under HP
Technology and any applicable copyright to reproduce, create derivative works,
publicly distribute, publicly perform and publicly display any improvements to
software originally created by Caliper (both source and

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

11
12

object code) for use in all fields. HP will provide updates to any such
improvements from time to time upon request of Caliper.

(e) PURCHASE OF PARTS. Caliper shall have the right to purchase
from HP for use in any Non-Collaboration Product any part manufactured or
supplied by HP that is incorporated into a Collaboration Product in development
or on the market, if Caliper cannot or elects not to manufacture such part or
have it manufactured. HP will identify such parts in HP's product design
documentation. Upon notification by HP, Caliper may elect to purchase such parts
from HP at any time during and after the term of this Agreement so long as such
parts are not obsolete. If Caliper elects to purchase such HP parts, promptly
after Caliper notifies HP of such election the parties shall agree on [ * ]. The
sale by HP of such parts shall be subject to HP's standard terms and conditions
of sale and service.

(f) LIMITED LICENSE FOR COLLABORATION PRODUCTS. Subject to the
terms and conditions of this Agreement, HP hereby grants to Caliper a worldwide,
fully-paid, non-exclusive, license, to develop, make, use, import and sell
Collaboration Products in accordance with Section 2.2(b)(ii), under HP
Technology, excluding any HP Confidential Information directed to HP's [ * ].

(g) ROYALTY CAP. The compensation due from Caliper to HP in
consideration for all HP intellectual property licensed to Caliper under
Sections 2.4(b) and 2.4(c) above shall not exceed royalties of [ * ]. The rates
set forth in this Section 2.4 are subject to adjustment as provided in Section
10.4(f). Payments due under this Section 2.4 shall be subject to the same terms
and conditions applicable to Gross Margin share payments on Collaboration
Products under Sections 7.6, 7.7 and 7.9. If any such product does not clearly
fall into one of the above classifications, the parties shall mutually agree on
an appropriate classification for such product prior to commercial introduction.

(h) RETAINED RIGHTS. All rights in HP Technology not expressly
granted to Caliper in this Agreement are retained exclusively by HP.

2.5 THIRD PARTY LICENSES

(a) EXISTING THIRD PARTY LICENSES. [ * ]. Each party acknowledges
that it is subject to the terms and conditions of any existing third party
licenses of the other party that it practices under this Agreement, so long as
such other party has provided a copy of the license agreement.

(b) FUTURE THIRD PARTY LICENSES. After the Effective Date, if
either HP or Caliper believes that additional intellectual property or
technology controlled by a Third Party ("Third Party Technology") is required or
desirable in order to proceed with the development or commercialization of one
or more Collaboration Products for use in the Field of Interest, then the
parties will discuss the situation in good faith [ * ].

2.6 MAJOR TRANSACTIONS. During the Collaboration, neither party may
enter into any agreement or arrangement respecting Collaboration Products [ * ]
for distribution or for the

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

12
13

purpose of [ * ], unless the other party gives written consent, which consent
will not be unreasonably withheld.

3. COLLABORATION MANAGEMENT

3.1 COLLABORATION PLANNING. The process of business planning will be
based upon Hewlett-Packard's Ten-Step Business Planning and Review Process. This
process is documented in various HP publications which have been made available
to Caliper at the Effective Date (Ref.: Booklet "Ten-Step Business Planning
Fundamentals" Hewlett-Packard Corporate Education Oct. 1997). The Business Plan
will include an assessment of customer needs and the competitive situation in
the markets addressed, a detailed 15-months Product Development Roadmap
including a 5-Year Product Development Vision, Marketing/Distribution and
Support, and Manufacturing Plans covering these periods and other elements as
deemed necessary by the parties. The parties will use reasonable business
efforts to complete the initial Business Plan at the end of the third month
following the Effective Date. The Business Plan will be at least reviewed on an
annual basis, revisions of the Business Plan being due at [ * ] of each year
during the term of the Collaboration. The process will be managed by the
Collaboration Managers of both parties, who designate Business Planning Teams
representing the functional areas of Marketing/Sales/Support, Research and
Development, Manufacturing and Finance.

3.2 COLLABORATION MANAGEMENT. The purpose of the Collaboration
management structure set forth below is to coordinate and expedite development
and commercialization of Collaboration Products. The activities of the parties
under this Agreement shall be managed in this structure only to the extent set
forth herein. Each party shall assign individuals from within their respective
organizations to each of the following positions. Each party may, in its sole
discretion, may replace the assigned individuals at any time as necessary.

(a) EXECUTIVE SPONSORS.

(i) APPOINTMENT; MEETINGS. Within thirty (30) days of the
Effective Date, each party shall appoint one (1) individual to be its Executive
Sponsor for the Collaboration. Each party's Executive Sponsor shall be a senior
executive of such party with the authority to make decisions on behalf of such
party.

(ii) RESPONSIBILITIES. The Executive Sponsors shall have the
following specific responsibilities:

(1) approving the Business Plan,

(2) settling disputes or disagreements that are
unresolved by the Collaboration Managers; and

13
14

(3) performing such other functions as appropriate to
further the purposes of this Agreement as determined by the parties.

(iii) DECISION-MAKING. The Executive Sponsors shall make
decisions by unanimous vote. Whenever the Executive Sponsors are unable to reach
a consensus on a particular issue, such issue shall be discussed [ * ].

(b) COLLABORATION MANAGERS.

(i) APPOINTMENT; MEETINGS. Within thirty (30) days of the
Effective Date, each party shall appoint one (1) individual to be its
Collaboration Manager. The Collaboration Managers shall meet monthly during the
term of the Agreement, unless otherwise mutually agreed by the parties. Meetings
of the Collaboration Managers will be held alternately at the facilities of the
parties in Palo Alto or Waldbronn or by teleconference. Each party shall
promptly report to the Collaboration Managers on all material issues relating to
the development or commercialization of the Collaboration Products. Minutes of
the meetings of the Collaboration Managers shall be prepared alternately by the
parties and such minutes shall be provided to the Executive Sponsors for review.

(ii) RESPONSIBILITIES. In addition to having the general
responsibility of conducting the business planning and review process of the
Collaboration in order to achieve the goal of the parties to develop and market
Collaboration Products, the Collaboration Managers shall have the following
specific responsibilities:

(1) directing the process of preparing the Business Plan
and the Product Plans. The first complete Business Plan will be prepared by the
Collaboration Managers within ninety (90) days of the Effective Date;

(2) updating and revising the Business Plan annually or
as mutually agreed;

(3) monitoring and reviewing the progress of research,
development, manufacturing, marketing, distribution and finance activities in
order to ensure that satisfactory progress is being made with respect to the
Business Plan and the Product Plans;

(4) discussing and agreeing upon remedial measures if
the Collaboration Managers determine that the progress for a particular project
covered by a Product Plan is unsatisfactory;

(5) settling disputes or disagreements that are
unresolved by the Product Program Managers;

(6) performing such other functions as appropriate to
further the purposes of this Agreement as determined by the parties.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

14
15
(iii) DECISION-MAKING. Decisions of the Collaboration
Managers shall be made by unanimous vote. If the Collaboration Managers become
deadlocked on an issue, the issue shall be presented to the Executive Sponsors
for resolution.

(c) PRODUCT PROGRAM MANAGERS. Each party shall appoint one of its
employees as a Product Program Manager for each System included in the Product
Plan. Such Product Program Manager will be responsible for overseeing the
day-to-day operations of such party with respect to such System and for
facilitating the achievement of agreed development milestones. A Product Program
Manager may be responsible for more than one such System.

(d) PROJECT TEAMS. Wherever practical, the Collaboration Managers
will consider teaming employees from one party to assist the other in areas
where those employees have relevant experience, provided that any disagreements
regarding staffing that cannot be resolved between the Collaboration Managers
will be resolved by [ * ].

4. DEVELOPMENT COLLABORATION

4.1 SCOPE. HP and Caliper will jointly develop Collaboration Products
in the Field of Interest during the term of the Collaboration. The activities
under the Collaboration will be governed by the Business Plan established
jointly by the parties. The parties agree to use the CAG Project Lifecycle
(Revision of October 1997 and future revisions) as the management tool for
establishing detailed Product Plans, Development Plans, Marketing/Sales/Support
Plans and Manufacturing Plans and for managing the execution and review of these
plans in a consistent and logical process framework. A copy of the CAG Project
Lifecycle will be provided to Caliper as reference material.

4.2 ALLOCATION OF DEVELOPMENT RESPONSIBILITIES.

(a) CALIPER RESPONSIBILITIES. Caliper will have Engineering
Responsibility for development of LabChips, [ * ]. With respect to LabChips,
this includes responsibility for development of processes for the manufacture of
LabChips.

(b) HP RESPONSIBILITIES. HP will have Engineering Responsibility
for Instruments. HP will have Engineering Responsibility for [ * ], subject to
Caliper's Engineering Responsibility as described in Section 4.2(a). The parties
expect that work on software will be particularly collaborative, with Caliper
generally focusing on the [ * ] portion of System Software and HP generally
focusing on [ * ]. HP will have responsibility for the overall system
integration of Collaboration Products, meaning that HP will make recommendations
to the party with Engineering Responsibility for each element regarding the
performance characteristics of such element that are necessary to ensure that
all elements function as a complete System when assembled.

(c) ALLOCATION OF FURTHER RESPONSIBILITIES IN THE DEVELOPMENT
PLANS. If Engineering Responsibility for an element of a Collaboration Product
is not specified by Sections 4.2(a) and 4.2(b) above, such responsibility will
be specified in the Development Plan. The

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

15
16

Collaboration Managers may mutually agree to assign Engineering Responsibility
differently than provided in Sections 4.2(a) and 4.2(b) above on a case-by-case
basis.

(d) POTENTIAL DEVELOPMENT BY HP. If HP proposes to develop a
System within the Field of Interest and if after joint discussion, Caliper
declines to develop the LabChip, [ * ] for such System, HP will have the right
to develop such LabChip, [ * ]; provided, however, HP's right to perform such
development is subject to HP's compliance with the provision under Section 7.2.
If HP develops such Collaboration Products, they shall be "HP Collaboration
Products" for purposes of this Agreement. In the event that HP elects to develop
an HP Collaboration Product, Caliper will provide [ * ].

4.3 EXCHANGE OF INFORMATION. Each party will share with the other
party relevant information in its possession that is necessary or useful for the
development of Collaboration Products. The parties will xxxxxx a spirit of
uninhibited exchange of information with the goal of creating an attitude of
joint project ownership in the parties' employees engaged in the development of
Collaboration Products.

4.4 DUE DILIGENCE. Each party shall use [ * ] efforts to carry out
development of each Collaboration Product in accordance with the mutually agreed
Product Plans, including applying the level of resources specified in such
plans; provided that Caliper's efforts are subject to HP providing funding under
Section 7.2. Any verification of such efforts will be performed by independent
auditors applying U.S. GAAP.

5. MANUFACTURING

5.1 MANUFACTURING RESPONSIBILITIES

(a) MANUFACTURE BY CALIPER. Except as set forth in Section 5.1(c)
below, Caliper shall be responsible for manufacturing and supplying all LabChips
[ * ] included in the Collaboration Products. Caliper may engage Third Parties
to manufacture and supply LabChips [ * ], provided that Caliper retains ultimate
responsibility for the final LabChips [ * ], and subject to Section 5.1(c).

(b) MANUFACTURE BY HP. HP shall be responsible for manufacturing
and supplying all Instruments, [ * ] included in the Collaboration Products. HP
may engage Third Parties to manufacture and supply Components, provided that HP
retains ultimate responsibility for the final Instruments, [ * ]. If HP supplies
Caliper with Instruments for use outside the Field of Interest or
post-Collaboration, the applicable supply document will provide that HP will not
make engineering changes after the manufacturing release of a product without
notification of Caliper.

(i) If Caliper elects not to manufacture LabChips for a
System included on the Product Plan, or if Caliper fails to meet minimum supply
commitments to be

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

16
17

agreed upon in future supply agreements under Section 5.2(b), HP shall have the
option to manufacture the LabChips not being supplied by Caliper.

(ii) If HP exercises its contingent manufacturing right for
LabChips as set forth under Section 5.1(c)(i), Caliper will provide HP [ * ]. If
HP develops new manufacturing processes and technology in the course of
manufacturing such LabChips, HP will provide Caliper [ * ].

(III) [ * ].

5.2 PRODUCTION PLANNING

(a) ESTABLISHMENT OF MANUFACTURING CAPACITY. The Collaboration
Managers shall develop a manufacturing plan (the "Manufacturing Plan") as part
of the Product Plan for each Collaboration Product, which shall be designed to
ensure sufficient supply of all Collaboration Products to satisfy market demand.

(b) LABCHIP SUPPLY AGREEMENTS. The sale of LabChips by Caliper to
HP will be governed by the terms and conditions of the OEM Purchase Agreement,
as outlined in Exhibit B hereto. In addition to the terms set forth in Exhibit
B, the following key terms are agreed to herein by the parties: (a) transfer
pricing will be as determined by and set forth in this Agreement, including
[ * ]; and (b) HP shall be obligated to buy, and Caliper shall be obligated to
sell, all of HP's requirements for such LabChips during the term of the
Collaboration. HP may revise any forecasts as set forth in the OEM Purchase
Agreement.

5.3 DUE DILIGENCE. Each party will use [ * ] business efforts in
manufacturing the Collaboration Products for which such party has manufacturing
responsibility.

6. MARKETING OF COLLABORATION PRODUCTS

6.1 SCOPE. HP will have the exclusive right to, and responsibility
for, marketing, selling, distributing and supporting Collaboration Products at
HP's expense in accordance with the terms of this Agreement and the Product
Plans jointly developed and agreed to by the parties as provided in Article 3,
except as otherwise specifically provided in this Agreement.

6.2 BRANDING.

(a) Caliper will xxxx LabChips supplied by Caliper with
appropriate "Caliper" and "LabChip" trademarks. Subject to HP's internal
trademark clearance procedures and Corporate Identity standards, Caliper will
also xxxx LabChips, or permit HP to xxxx LabChips, with the HP company and
product trademarks as a prominent sub-brand.

(b) Subject to HP's internal trademark clearance procedures and
Corporate Identity standards relating to co-branding, HP will xxxx, or allow
Caliper to xxxx, all System

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

17
18

Components including Instruments, Reagents and Software with appropriate
"Caliper" and "LabChip" trademarks as a prominent sub-brand.

6.3 DISTRIBUTORS. [ * ]

6.4 PACKAGING AND LABELING. The Collaboration Products for commercial
sale under this Agreement shall be packaged and labeled consistent with the
requirements of the applicable laws of the countries where a Collaboration
Product is sold.

(a) The parties agree to discuss patent marking on a case-by-case
basis prior to product introduction in accordance with HP internal guidelines on
patent marking to preserve patent rights or protect the product from
infringement. If applicable, such patent marking shall identify HP and Caliper
as the manufacturers of such Collaboration Product.

(b) The parties agree to label Collaboration Products in a way
that makes it clear that no license is granted for diagnostic use but that does
not hurt marketing efforts.

6.5 ADVERTISING, PROMOTIONAL AND EDUCATIONAL MATERIALS. The parties
shall mutually establish guidelines for the use of HP's and Caliper's corporate
names, logos and trademarks in written sales, promotional, educational and
advertising materials relating to Collaboration Products. All such written and
visual materials and all documentary information and promotional materials will
portray HP, Caliper and their respective corporate names, logos and trademarks
in a manner consistent with their respective roles under this Agreement.

6.6 CUSTOMER SUPPORT. HP shall manage the customer interface and
shall provide a first level of service and support to end-user customers for all
Collaboration Products. Caliper will use reasonable business efforts to provide
backup technical support to HP. The Collaboration Managers will agree on a
mechanism by which Caliper will provide such backup technical support and obtain
direct end-user customer feedback regarding Collaboration Products. [ * ].

6.7 DUE DILIGENCE. HP will [ * ]. HP shall use [ * ] efforts in
marketing, promoting, selling and supporting the Collaboration Products.

7. FINANCIAL AND COMMERCIAL TERMS

7.1 EQUITY INVESTMENT. Within three days after the Effective Date,
the parties shall enter into a Preferred Stock Purchase Agreement, pursuant to
which HP shall pay to Caliper a total amount of [ * ].

7.2 DEVELOPMENT FUNDING.

18
19

(a) MINIMA. HP will provide projects for development of
Collaboration Products by Caliper sufficient to meet the funding minima set
forth in this section. HP will pay Caliper Development Expenses for such
projects in the minimum amount of [ * ] dollars during [ * ], provided Caliper
actually incurs that amount of Caliper Development Expenses. HP will pay Caliper
Development Expenses for such projects in the minimum amount of [ * ] dollars in
the aggregate during years [ * ], provided Caliper actually incurs that amount
of Caliper Development Expenses. HP will pay Caliper Development Expenses for
such projects in the minimum amount of [ * ] dollars per year during years
[ * ], provided Caliper actually incurs that amount of Caliper Development
Expenses.

(b) CHANGES IN FUNDING LEVEL. Subject to the requirements of
subparagraph 7.2(a) above, at the start of year [ * ] HP may reduce or increase
the amount of Caliper Development Expenses that HP will pay for during year
[ * ] as compared with the actual funding in year [ * ] by any amount up to
[ * ], or a larger amount with Caliper's advance consent. Similarly, at the
start of year [ * ] HP may reduce or increase the amount of Caliper Development
Expenses that HP will pay for during year [ * ] as compared with the actual
funding in year [ * ] by any amount up to [ * ], or a larger amount with
Caliper's advance written consent. At the start of any subsequent year HP may
increase the amount of Caliper Development Expenses that HP will pay for during
such year as compared with the actual funding in the previous year by [ * ]
percent [ * ], or a larger amount with Caliper's advance written consent.

(c) HP will advance funds to Caliper on a monthly basis
sufficient to pay for the Caliper Development Expenses estimated and agreed to
for work to be conducted during each year under the Product Plan. Such payments
will be independent of any goals or milestones set forth in the Product Plan.

(d) Caliper will report actual incurred Caliper Development
Expenses by project to HP quarterly, not later than thirty days after the end of
each quarter. The report will include the information specified in the
definition of "Caliper Development Expenses".

(e) Deviations between amounts advanced by HP and actual incurred
Caliper Development Expenses at the end of each quarter will be carried over to
the next quarter and will reduce or increase the estimated funding payments for
the following month. Deviations at the end of any year will be carried over to
the following year.

(f) [ * ] used in calculating Caliper Development Expenses will
be reviewed annually and [ * ] will be adjusted by mutual agreement. The [ * ]
includes but is not necessarily limited to [ * ].

7.3 HP OPERATING EXPENSES

(a) YEARS [ * ]. HP shall expend not less than [ * ] in HP
Operating Expenses during the first [ * ] of the Agreement, including at least
[ * ] in Caliper Development Expenses funded by HP pursuant to Section 7.2.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

19
20

(b) YEARS [ * ]. If HP desires to continue the Collaboration
after the [ * ] anniversary of the Effective Date, HP shall expend at least
[ * ] dollars [ * ] in HP Operating Expenses in the [ * ] year of the Agreement
and at least [ * ] dollars [ * ] in HP Operating Expenses in the [ * ] year of
the Agreement, again including Caliper Development Expenses funded by HP. HP
shall notify Caliper in writing at least one hundred and thirty five (135) days
prior to the [ * ] of the Effective Date, respectively, whether it will or will
not meet its spending requirements for Caliper Development Expenses and HP
Operating Expenses for the following year. In the event HP does not make such
spending commitments for [ * ] either party may terminate the Collaboration,
pursuant to Section 10.5.

(c) YEARS [ * ]. At the beginning of year [ * ] of the
Collaboration, the parties shall initiate discussions regarding the appropriate
level of HP Operating Expenses or alternative performance criteria which HP must
meet in each of the [ * ] years of the Collaboration.

(d) CREDIT FOR EXCESS SPENDING. If HP expends HP Operating
Expenses in excess of the amounts required in a particular year of the
Collaboration, such excess amounts shall be carried forward and applied against
the HP Operating Expense requirement in any subsequent year up to the end of
year [ * ]. In no event, however, may funding for Caliper Development Expenses
be reduced below the minima provided in Section 7.2.

(e) CERTIFICATION BY HP. Within forty five (45) days after the
last day of each year of the Collaboration, HP shall provide to Caliper (i)
written certification by an appropriate HP financial officer that HP has
expended the minimum amounts for HP Operating Expenses to date and (ii) a report
of the cumulative HP Operating Expenses as of the last day of the applicable
year.

7.4 CALIPER OPERATING EXPENSES

(a) YEARS [ * ]. Caliper together with its Third Party
collaborators shall expend not less than [ * ] dollars [ * ] in Caliper
Operating Expenses during the first [ * ] years of the Agreement.

(b) YEARS [ * ]. The parties intend that the Caliper Operating
Expenses will be at least [ * ] dollars [ * ] in the [ * ] year of the Agreement
and at least [ * ] dollars [ * ] in the [ * ] year of the Agreement. However,
Caliper's expenditure of such amounts is at Caliper's sole discretion. Caliper
will notify HP in writing at least [ * ] days prior to the anniversary of the
Effective Date in years [ * ] whether it will or will not meet its spending
requirements for Caliper Operating Expenses for such years. If Caliper notifies
HP that it will not meet such spending requirements for either year [ * ], then
HP shall not be required to meet the HP Operating Expense requirements of
Section 7.3 for such year. HP's obligations under Section 7.2 shall not be
affected however. All other terms of this Agreement shall continue in such
event, and neither party shall have the right to terminate this Agreement
pursuant to Article 10.

(c) YEARS [ * ]. At the beginning of the [ * ] year of the
Collaboration, the parties shall initiate discussions regarding the appropriate
level of Caliper Operating Expenses or

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

20
21

alternative performance criteria which Caliper must meet in each of the [ * ]
years of the Collaboration. Such obligations shall be determined in view of the
[ * ], and other reasonable criteria which either party may wish to discuss in
good faith.

(d) CREDIT FOR EXCESS SPENDING. If Caliper expends Caliper
Operating Expenses in excess of the amounts required in a particular year of the
Collaboration, such excess amounts shall be carried forward and applied against
the Caliper Operating Expense requirement in any subsequent year up to the end
of year [ * ].

(e) CERTIFICATION BY CALIPER. Within forty five (45) days after
the last day of each year of the Collaboration, Caliper shall provide to HP (i)
written certification by an appropriate Caliper financial officer that Caliper
has expended the appropriate amounts for Caliper Operating Expenses to date and
(ii) a report of the cumulative Caliper Operating Expenses as of the last day of
the applicable year.

(f) [ * ], such Caliper Operating Expenses will be recognized in
full only when such [ * ] is no longer [ * ] and provided such [ * ] is relevant
to the Field of Interest as reasonably determined by Caliper.

7.5 GROSS MARGIN SHARING

(a) COLLABORATION PRODUCTS. During the term of the Collaboration,
HP and Caliper will share the Gross Margin on all Collaboration Products as
follows, on a product-by-product basis:

Class A Products [ * ] [ * ]

Class B Products [ * ] [ * ]

Class C Products [ * ].

If any product does not clearly fall into one of the above classifications, or
there is disagreement between the parties as to which category a particular
product falls into, the parties shall mutually agree on an appropriate Gross
Margin sharing rate for such product in connection with Product Plan
discussions, before commercial manufacture begins.

That portion of the Gross Margin generated by System Software which will be
considered to be attributable to a Class A Product will be calculated by [ * ].
That portion of the Gross Margin generated by System Software which will be
considered to be attributable to a Class B Product will be calculated by [ * ].

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

21
22

(b) HP COLLABORATION PRODUCTS. If Caliper elects not to develop a
LabChip and HP performs the development of such LabChip as set forth in Section
4.2(d), then HP and Caliper will share Gross Margin on the System in which the
LabChip is used as follows:

(i) if Caliper elects to manufacture the LabChip:

Class A Products [ * ] [ * ]

Class B Products [ * ] [ * ]

Class C Products [ * ].

(ii) if Caliper elects not to manufacture the LabChip:

Class A Products [ * ] [ * ]

Class B Products [ * ] [ * ]

Class C Products [ * ].

(c) ADJUSTMENTS. The parties acknowledge that the Gross Margin
share percentages set forth above have been negotiated based in part upon the
assumption that the average discount (as per the AFM) for Collaboration
Products, treated as a class, will be similar to the average discount for HP
Chemical Analysis Group's non-Collaboration Products. Accordingly, the parties
will review the average discount for all Collaboration Products on the [ * ]
anniversary of the Effective Date, and [ * ] thereafter, in each case reviewing
the previous [ * ] period. If the average discount for Collaboration Products in
any such [ * ] period is more than [ * ] percent [ * ] above or below the
average discount for non-Collaboration Products in such period, then the parties
shall meet and reasonably discuss in good faith corresponding changes to the
Gross Margin share percentages and HP Operating Expense commitments.

(d) TRANSFER OF PRODUCTS: All Collaboration Products supplied by
Caliper and shipped to HP will be invoiced to HP at Caliper's Transfer Price and
HP will pay against such invoice. This price will be part of HP's Cost of Sales
and therefore part of the Gross Margin calculation.

(e) INTEGRATED [ * ] PRODUCTS. Where HP's [ * ] technology is
integrated into a Collaboration Product, the parties will mutually agree, prior
to entry into the laboratory prototype phase, on a Gross Margin sharing rate
that reflects the proportional value of HP's [ * ] technology to the value of
the Caliper Technology. The Gross Margin share rate applicable to the value of
HP's [ * ]. Where the [ * ] qualifies as a Class C Product, [ * ].

7.6 BUNDLING AND PRICING. HP will establish prices for Components
that reflect in good faith the [ * ]. Furthermore, the parties understand that
certain Collaboration Products may be sold together as a kit or separately, as
customers may require from time to time. The Gross Margin of Collaboration
Products sold together in a kit shall be shared pursuant to the Gross

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

22
23

Margin share rules set forth in Section 7.5 based on [ * ]. If [ * ], the
parties shall mutually agree on an appropriate Gross Margin sharing rate for
such Collaboration Product in connection with Product Plan discussions, before
[ * ]. HP will individually price such bundled Collaboration Products in
accordance with [ * ] calculated as set forth in this Section 7.6. After the
initial sale of bundles consisting of [ * ], the [ * ] will be sold at prices
that are [ * ]. [ * ].

7.7 CASH FLOW

(a) Payment for Caliper Development Expenses will be made monthly
in advance on the first workday of the month.

(b) Caliper's Gross Margin share will be paid not later than the
last workday of the month following the shipment month of the Collaboration
Product.

(c) Royalty payments for New Products will be paid quarterly
(based on HP's fiscal year quarter) not later than the last workday of the month
following the shipment quarter.

(d) Payment for all products supplied by Caliper and shipped to
HP will be made in accordance with the applicable OEM contract.

7.8 COST OF SALES

(a) REVISION OF TRANSFER PRICE. The Transfer Price will reflect
[ * ]. The Transfer Price will be revised at least twice a year [ * ]. If the
[ * ], the Transfer Price must also be revised prospectively (per interim
revision rules of the AFM).

(b) EXCESS CAPACITY COSTS. Excess capacity costs (machinery and
personnel) will [ * ]. In the event that manufacturing capacity extensions
result in excess capacity, then [ * ]. The maximum capacity achievable through
said capacity extension and its related impact on [ * ] will be mutually agreed
to in advance.

7.9 ACCOUNTING AND AUDIT

(a) HP will follow HP's standard financial practices, processes
and procedures as listed in the AFM. Caliper will follow the U.S.GAAP and will
make reasonable efforts to follow HP's standard financial practices, processes
and procedures as listed in the AFM. HP will disclose the AFM and any other
appropriate information to Caliper as necessary to enable Caliper to do this.

(b) All Gross Margin share and royalty payments made pursuant to
this Agreement will be accompanied by a report detailing the calculation of such
payments. Each party will keep adequate records regarding the basis for such
calculations in accordance with its standard practices but in no event for less
than three years.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

23
24

(c) Each party may audit the financial records of the other party
for the limited purpose of ensuring compliance with the financial obligations of
that other party under this Agreement. Such an audit may be conducted not more
often than annually, during regular business hours, and on reasonable advance
notice. Such audit will be conducted by an independent auditor which will be
obligated to keep strictly confidential the audited party's financial records
and other information. The auditor will disclose such information to the
auditing party only to the extent necessary to establish compliance or
non-compliance with the audited party's financial obligations and, if the
latter, the magnitude of any discrepancy. The auditing party will pay the costs
of such audit unless the audit shows that the audited party is more than [ * ]
percent [ * ] delinquent in its obligations for the period of the audit as of
the end of such period, in which case the audited party will pay the costs of
the audit.

8. INTELLECTUAL PROPERTY MATTERS

8.1 REPRESENTATIONS AND WARRANTIES. Each party warrants that it has
the right to grant the licenses set forth in Section 2 of this Agreement.
Neither party: (a) makes any other representations or warranties, express or
implied, (b) assumes any liability with respect to any infringement of patents
or other rights of third parties due to the other party's operation under the
licenses granted herein, (c) assumes any responsibility for enforcement of its
Licensed Patents against third parties; or (d) assumes any responsibility for
continued maintenance of any Licensed Patent.

8.2 OWNERSHIP OF TECHNOLOGY

(a) Caliper shall retain all right, title and interest in and to
the Caliper Technology, and to any and all software, inventions, discoveries and
information made or developed solely by Caliper in the course of the
Collaboration, subject only to the licenses expressly granted to HP hereunder.

(b) HP shall retain all right, title and interest in and to the
HP Technology, and to any and all software, inventions, discoveries and
information made or developed solely by HP in the course of the Collaboration,
subject only to the licenses expressly granted to Caliper hereunder.

(c) The parties will jointly own all Joint Inventions (the term
"Joint Inventions" is defined in Section 8.3(b)). The parties shall each have
full rights of joint ownership of such Joint Inventions without restriction to
the Field of Interest. Each party may exploit patents on any Joint Inventions
[ * ]. In particular, each party may use a Joint Invention or a patent thereon
[ * ].

8.3 PATENT PROSECUTION AND MAINTENANCE

(a) SOLE INVENTIONS.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

24
25

(i) A "Sole Invention" is an invention or improvement
conceived entirely by one or more employees of Caliper or by one or more
employees of HP in the course of the Collaboration.

(ii) Each party shall have the right, but not the obligation,
at its expense and using patent counsel of its choice, to file, prosecute and
maintain patent applications claiming its Sole Inventions.

(iii) [ * ].

(b) JOINT INVENTIONS.

(i) A "Joint Invention" is an invention or improvement
conceived jointly by one or more employees of Caliper and one or more employees
of HP in the course of the Collaboration. The determination of whether an
invention or improvement is conceived "jointly" will be made under United States
law by assuming all the inventors were United States citizens and were located
within the territorial limits of the United States at the time of conception,
regardless of the actual nationality of the inventors or the actual location
where the invention was conceived.

(ii) The parties shall confer to determine how to allocate
responsibility and expenses for filing, prosecuting and maintaining patent
applications claiming any Joint Inventions. Unless the parties mutually agree
otherwise, Caliper shall have the right to file, prosecute and maintain patent
applications claiming Joint Inventions relating primarily to Lab-on-a-Chip
Technology and HP shall have the right to file, prosecute and maintain patent
applications claiming Joint Inventions relating primarily to Instruments. If the
party determined to be responsible elects not to file and prosecute applicable
patent applications on such Joint Inventions, the other party may undertake such
prosecution at its own expense in both parties' names. Each party is responsible
for compliance with any inventor law provisions and for any legally required
inventor compensation of its employees

(c) MUTUAL DISCLOSURE OF PATENT APPLICATIONS. If either party
files a patent application covering a Sole or Joint Invention, the filing party
will promptly disclose such patent application to the other party. The filing
party will keep the other party reasonably informed of the course of patent
prosecution or other proceedings with regard to such patent applications and
will provide reasonable advance notice to the other party of all filings and
correspondence with patent authorities regarding such patent applications,
including without limitation office actions, responses to office action,
amendments, restrictions, elections, requests for terminal disclaimer, and
requests for reissue or reexamination of any patent issuing from such
application, and any election to discontinue prosecution or maintenance thereof.
The other party will have an opportunity to review and comment on such filings
and correspondence prior to any applicable filing deadline.

(d) LICENSED PATENTS. Each party will promptly inform the other
if it elects to discontinue prosecution or maintenance of any patent or patent
application licensed hereunder.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

25
26

8.4 THIRD PARTY PATENTS

(a) PATENT REVIEW. [ * ]. The parties agree to proactively review
relevant Third Party patents on a periodic basis and discuss any such Third
Party patents that represent a material risk of such infringement. Either party
may elect at any time to cease developing, manufacturing or distributing any
Collaboration Product that it reasonably determines on the advice of counsel
poses a substantial risk of infringing a third party patent.

(b) NOTICE OF CLAIMS. If the use, manufacture or sale of
Collaboration Products within the Field of Interest results in a claim, suit or
action, or an overt threat of same, (collectively, "Claims") against either or
both parties for patent infringement or for inducing or contributing to patent
infringement, the party first having notice of such Claim shall promptly notify
the other. The notice shall set forth the facts of such Claim in reasonable
detail.

(d) NO ESCROW. No payments under this Agreement shall be subject
to escrow or otherwise delayed or waived by reason of any patent litigation.

8.5 INFRINGEMENT CLAIMS AGAINST THIRD PARTIES

(a) NOTIFICATION. If a Third Party infringes or misappropriates
any Caliper Technology or HP Technology by commercializing products in the Field
of Interest, the party to this Agreement first having knowledge of such
infringement or misappropriation shall promptly notify the other in writing. The
notice shall set forth the available facts of such infringement or
misappropriation in reasonable detail. The parties shall discuss the matter
[ * ].

(b) PROSECUTION OF INFRINGEMENT ACTIONS. The owner of the patent
or trade secret that is the subject of infringement or misappropriation shall
have the primary right, but not the obligation, to institute, prosecute and
control any action or proceeding with respect to infringement or
misappropriation of such patent or technology by counsel of its own choice. If
an infringement action infringes on both Caliper Technology and HP Technology,
the parties shall coordinate their prosecution with respect to such
infringement. The parties shall confer to determine which party shall have the
primary responsibility to institute, prosecute and control any action or
proceeding with respect to misappropriation of trade secrets or infringement of
patents claiming Joint Inventions.

(d) EXPENSES AND RECOVERY. If the parties mutually agree to
prosecute an enforcement action, then they will also agree [ * ].

9. CONFIDENTIALITY

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

26
27

9.1 CONFIDENTIALITY. Except to the extent expressly authorized by
this Agreement or otherwise agreed in writing by the party who originally
disclosed such Confidential Information (the "Disclosing Party"), the party to
whom such Confidential Information was disclosed (the "Recipient") agrees to
keep the Disclosing Party's Confidential Information strictly confidential, as
if it were its own, for five years from the date of disclosure. Furthermore,
neither party shall use Confidential Information for any purpose other than for
performing its obligations or exercising its rights under this Agreement, except
that general business information may be used (but not disclosed) in the
ordinary course of business.

9.2 EXCEPTIONS. The above obligations of non-disclosure and non-use
shall not apply to information of which the recipient can document that:

(a) it was in the public domain at the time it was communicated
to the recipient by the disclosing party;

(b) it entered the public domain subsequent to the time it was
communicated to the recipient by the disclosing party through no fault of the
recipient;

(c) it was in the recipient's possession free of any obligation
of confidence at the time it was communicated to the recipient by the disclosing
party;

(d) it was rightfully communicated to the recipient free of any
obligation of confidence subsequent to the time it was communicated to the
recipient by the disclosing party;

(e) it was independently developed by employees or agents of the
recipient who had no knowledge of any Confidential Information communicated to
the recipient by the disclosing party;

(f) the communication was in response to a valid order by a court
or other governmental body, was otherwise required by law, or was necessary to
establish the rights of either party under this Agreement.

9.3 AUTHORIZED DISCLOSURES

(a) Notwithstanding Sections 9.1 and 9.2 above, the parties
hereby acknowledge each other's right to disclose Confidential Information to
Third Parties with whom they have entered into agreements for the purpose of
developing and commercializing Collaboration Products. If either party desires
to disclose any of the other's Confidential Information for the purposes set
forth in the preceding sentence, the parties shall meet to review such planned
disclosure and shall mutually agree on the Confidential Information, if any, to
be so disclosed prior to any such disclosure by either party.

(b) Notwithstanding Sections 9.1 and 9.2 above, each party may
disclose Confidential Information belonging to the other party to Affiliates and
sublicensees who agree to be bound by terms of confidentiality at least as
stringent as those in this Article 9. In addition, each party may disclose
Confidential Information of the other party to the extent such disclosure

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

27
28

is reasonably necessary to: (i) comply with applicable securities laws and
regulations and other applicable governmental regulations, (ii) file or
prosecute patents relating to Sole Inventions or Joint Inventions, and (iii)
prosecute or defend litigation relating to Collaboration Products.
Notwithstanding the foregoing, in the event a party is required to make a
disclosure of Confidential Information as provided in this Section 9.3, it will,
except where impracticable, give reasonable advance notice to the other party of
such disclosure and use reasonable business efforts to maintain the information
as confidential or to secure confidential treatment of such information. In any
event, the parties agree to take all reasonable action to avoid disclosure of
Confidential Information hereunder.

9.4 COMMUNICATION AND PUBLICITY

(a) Promptly after the Effective Date, the parties may announce
the establishment of the Collaboration under this Agreement and its key terms in
a mutually agreed press release issued simultaneously by both parties. Subject
to the further provisions of this Section, no party shall originate any
subsequent written publicity, news release, or other announcement relating to
this Agreement or to performance hereunder or the existence of an arrangement
between the parties (collectively, "Written Disclosure"), without the prior
prompt review and written approval of the other. Once specific information has
been approved for disclosure, that information may be reiterated in any
subsequent Written Disclosure without further approval.

(b) Notwithstanding the foregoing provisions of this Article 9,
any party may make any public Written Disclosure it believes in good faith based
upon the advice of counsel is required by applicable law or any listing or
trading agreement concerning its publicly traded securities, provided that prior
to making such Written Disclosure, the disclosing party shall provide the other
party with a copy of the materials proposed to be disclosed and provide such
party with an opportunity to review and comment on the proposed Written
Disclosure.

(c) The terms of this Agreement may be disclosed to Third Parties
so long as such disclosure is made under a binder of confidentiality and so long
as material financial terms are not disclosed.

10. TERM AND TERMINATION

10.1 TERM.

(a) The term of the Collaboration will commence on the Effective
Date and will expire on the eighth (8th) anniversary of the Effective Date (the
"Expiration Date") unless earlier terminated pursuant to this Article 10.

(b) This Agreement will become effective upon the Effective Date
and continue until the last to expire payment obligation of either party, unless
terminated earlier pursuant to this Article 10.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

28
29

10.2 TERMINATION FOR BREACH.

(a) Either party may terminate this Agreement for material breach
of the Agreement by the other party on [ * ] written notice. The notice will
describe the breach in detail, and the allegedly breaching party will have [ * ]
in which to cure such breach.

(b) If during the Collaboration Caliper fails to cure a material
breach within such [ * ] period, HP at its option may terminate this Agreement
or may continue the Agreement in force. If HP elects to continue this Agreement
in force, HP may [ * ] for the remaining term of the Agreement.

(c) If during the Collaboration HP fails to cure a material
breach within such [ * ] period, Caliper at its option may terminate this
Agreement or may continue the Agreement in force. If Caliper elects to continue
this Agreement in force, Caliper may [ * ] for the remaining term of the
Agreement.

(d) If HP terminates the Agreement due to a Clear and Serious
Breach by Caliper (as described below), which breach remains uncured after the [
* ] day cure period, then upon termination the rights and obligations set forth
below in Section 10.4 for early termination after year five and beyond will
apply. For purposes of this Section, a "Clear and Serious Breach" shall mean
that Caliper materially breaches the Agreement by either (i) failing to apply at
least [ * ] percent [ * ] of the Caliper resources set forth in applicable
Product Plans in any year or (ii) willfully selling products that are clearly
within HP's exclusive rights in the Field of Interest as set forth in Article 2
above, either directly or through Third Parties, [ * ]. The rights and
obligations set forth in Section 10.4 shall not apply if the alleged breach is
the subject of a dispute resolution proceeding under Section 12.2 or if the
failure to perform results from Force Majeure as set forth in Section 13.2.

(e) The remedies set forth in subsections (b), (c) and (d) above
are in addition to any other remedies to which the parties may be entitled.

10.3 TERMINATION FOR CONVENIENCE. Either party may terminate the
Collaboration for any reason or no reason with at [ * ] prior written notice,
such termination to be effective at any time after the fifth anniversary of the
Effective Date. The date on which the termination takes effect is referred to
herein as the "Termination Date".

10.4 EFFECT OF EXPIRATION OR TERMINATION. If the Collaboration
expires at the end of its eight-year term, or if the Collaboration is terminated
for breach under Section 10.2(d) or for convenience under Section 10.3, then:

(a) PAYMENTS. Any outstanding payment obligations must be
satisfied as of the Termination or Expiration Date. Any overpayment must be
returned forthwith.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

29
30

(b) RESEARCH AND DEVELOPMENT. All joint research and development
under the Collaboration and HP funding of such research and development will end
on the Termination or Expiration Date.

(c) SUPPLY OF PRODUCTS BY CALIPER. For [ * ] years following the
Termination or Expiration Date, HP will have the option to have Caliper continue
to supply HP with all Collaboration Products being supplied by Caliper as of the
Termination or Expiration Date. Whether or not HP elects to have Caliper supply
such Collaboration Products, the financial terms will be as set forth in Section
10.4(h) below, subject to Section 10.4(f).

(d) SUPPLY OF PRODUCTS BY HP. For [ * ] years following the
Termination or Expiration Date, HP will supply all of Caliper's requirements for
Collaboration Products being supplied by HP as of the Termination or Expiration
Date. Pricing and other terms shall be [ * ].

(e) TRAINING. During the [ * ] after any notice of termination is
given pursuant to this Article 10, or during the first [ * ] after the fifth
anniversary of the Effective Date if such notice is given before the fifth
anniversary of the Effective Date, the party manufacturing and supplying a
Component will [ * ] to instruct and train personnel of the other party so that
the other party will [ * ] manufacture and supply such Components in a similar
manner. Additional instruction and training will be provided upon reasonable
request during the ensuing [ * ] period, provided the requesting party
reimburses the other party's [ * ]. If the Collaboration is terminated for Clear
and Serious Breach, such training will be given during the [ * ] period after
such termination becomes effective, and not during the pendency of any dispute
resolution proceeding respecting such termination.

(f) [ * ].

(g) RIGHTS TO COMMERCIALIZE COLLABORATION PRODUCTS. After the
Termination or Expiration Date, HP shall have a worldwide, non-exclusive,
non-transferable license under Caliper Technology and software to market, sell
and support Collaboration Products in the Field of Interest. Caliper shall also
have the right to market, sell and support Collaboration Products, independently
or with Third Parties; provided, however, that if the Termination Date occurs
within a period of time that begins [ * ] years after the Effective Date and
ends [ * ] years and [ * ] months after the Effective Date, Caliper may not
market, sell or support Collaboration Products in the Field of Interest during
such period. Notwithstanding the foregoing, neither party may enter into an
agreement [ * ] for the sale of the Collaboration Products during the [ * ]
months following the Expiration or Termination Date. After such [ * ] month
period, either party may enter into any agreement with any Third Party

(h) PAYMENTS ON COLLABORATION PRODUCTS AFTER TERMINATION. After
the Termination or Expiration Date, HP shall pay Caliper the percentage of the
Gross Margin from sales of all Class A and Class B Collaboration Products during
the respective time periods as follows and shall [ * ] for Collaboration
Products supplied by Caliper. The rates set forth below

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

30
31

are subject to the adjustment as provided in Section 10.4(f). These payments
will be made on the same schedule and terms as during the Collaboration under
Article 7 and will continue [ * ].

PRODUCT [ * ] MONTHS [ * ] MONTHS FOLLOWING MORE THAN [ * ] MONTHS
FOLLOWING TERMINATION FOLLOWING TERMINATION FOLLOWING TERMINATION

CLASS A PRODUCTS

Collaboration Products [ * ] [ * ] [ * ]
other than HP
Collaboration Products

HP Collaboration Products; [ * ] [ * ] [ * ]
LabChip manufactured by
Caliper*

HP Collaboration Products; [ * ] [ * ] [ * ]
LabChip manufactured by
HP*

CLASS B PRODUCTS [ * ] [ * ] [ * ]

-----------------

*These Gross Margin rates only apply if Caliper elects not to develop a LabChip
and HP performs the development of such LabChip as set forth in Section 4.2(d).

(i) COMMERCIALIZATION OF NEW PRODUCTS.

(i) HP RIGHTS. In the event of expiration or termination of the
Collaboration pursuant to Section 10.4, Caliper agrees to grant to HP a
non-transferable (except to a successor in interest to the HP Chemical Analysis
Group), royalty-bearing, worldwide, non-exclusive license under certain of the
Caliper Technology specified in this Section to develop, manufacture, market,
sell and support products in the Field of Interest. The products developed
pursuant to this license and covered by Caliper Patents will be "New Products,"
as defined in Article 1. Such license will be subject to the following potential
adjustments over time.

(1) The through-put limits applicable to this license will
continue to be subject to adjustment to ensure a leading edge relative to the
competition pursuant to Section 2.2(a)(ii) as applied to Collaboration Products,
and New Products which HP may

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

31
32

develop, after the Collaboration ends. In addition, the through-put limits
applicable to this license will be proactively adjusted as follows to maintain
parity with programs established by Caliper or its other licensees to develop
products utilizing Caliper Technology with higher through-put for sale on the
market in the Field of Interest. If Caliper [ * ], or if Caliper grants any
Third Party the right [ * ], then in either of such events Caliper shall
promptly notify HP in writing of such fact and the nature of the Application(s)
[ * ], and the through-put limits applicable to HP's license will automatically
be adjusted to [ * ] with respect to such Application(s).

(2) On the [ * ] anniversary of the Termination or Expiration
Date, HP will deliver to Caliper a written notice that lists the patents and
patent applications within the Caliper Technology that HP intends to use in New
Products for which [ * ]. Any patents or patent applications within the Caliper
Technology not listed in the notice will then be removed from the non-exclusive
license granted to HP under this Section 10.4(i)(i).

(3) On the [ * ] anniversary of the Termination or Expiration
Date, HP will deliver to Caliper a written notice that lists the patents and
patent applications within the Caliper Technology from the list provided under
clause (i) above that HP still intends to use in New Products for which [ * ].
Any patents or patent applications within the Caliper Technology not listed in
the notice will then be removed from the non-exclusive license granted to HP
under this Section 10.2(i)(i).

(4) Upon the [ * ] anniversary of the Termination or
Expiration Date, the patents and patent applications within the Caliper
Technology subject to the non-exclusive license granted under this Section
10.4(i)(i) shall be limited to the patents and patent applications listed as
aforesaid and actually utilized [ * ] prior to that date.

(ii) CALIPER RIGHTS. In the event of expiration or termination of
the Collaboration pursuant to Section 10.4, Caliper will retain exclusive rights
(except for the non-exclusive license granted to HP under Section 10.4(i)(i)
above) under Caliper Technology to make, use and sell products for all uses in
the Field of Interest. Caliper will retain all licenses to HP Technology granted
under the Collaboration and will continue to have access to HP Patents, System
Software and parts as provided in Section 2.4. Caliper will be free to develop
and market new systems that are compatible with all Collaboration Products.

(iii) ROYALTIES ON NEW PRODUCTS. HP shall pay royalties to
Caliper on all Net Revenues from the sale of New Products in Class A and Class B
as set forth below, provided that and for so long as the manufacture, use or
sale of at least one Component in the applicable class (Class A or Class B) is
claimed in a Caliper Patent in the country of manufacture, use or sale,
respectively. The royalty rates [ * ]. All of the rates set forth in this
Section 10.4(i)(iii) are subject to adjustment as provided in Section 10.4(f).

ROYALTY RATE [ * ] CLASS A PRODUCTS [ * ] CLASS B PRODUCTS
(PERCENT OF NET REVENUES)

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

32
33

[ * ] [ * ] [ * ]

Class C Products [ * ].

That portion of the royalty arising from System Software which will be
considered to be attributable to a Class A Product will be calculated by [ * ].
That portion of the royalty arising from System Software which will be
considered to be attributable to a Class B Product will be calculated by [ * ].

If any New Product does not clearly fall into one of the above classifications,
the parties shall mutually agree on an appropriate royalty rate for such New
Product prior to commercial introduction.

[ * ].

By way of example, [ * ].

Payments due under this Section 10.4(i)(iii) shall be subject to the same terms
and conditions applicable to Gross Margin share payments on Collaboration
Products under Sections 7.6, 7.7 and 7.9.

Where HP's [ * ] technology is integrated into a New Product, the parties will
mutually agree, prior to commercial launch, on a royalty rate that reflects the
proportional value of HP's [ * ] technology to the value of the Caliper
Technology. The royalty rate applicable to the value of HP's [ * ] will be [ * ]
percent and the rate applicable to the value of the Caliper Technology will be
the [ * ] under this Agreement. Where the [ * ] qualifies as a Class C Product,
[ * ].

(iv) ACCESS TO DISTRIBUTION CHANNELS. After any notice of
termination is given by either party, each party will review all its
relationships with Third Parties who had sales of Collaboration Products in the
previous year consisting of more than [ * ]. If there are any agreements or
arrangements with such Third Parties that would make it commercially impractical
for Caliper to sell Collaboration Products or New Products through such Third
Parties after the Collaboration ends, then the parties will agree in good faith
on practical means to ensure Caliper such ability.

10.5 TERMINATION OF COLLABORATION PRIOR TO THE FIFTH YEAR.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

33
34

(a) Either party may terminate the Collaboration, with at least [ * ]
written notice, at any time if HP does not commit in writing to Caliper to meet
the HP Operating Expense commitments as provided in Section 7.3 or actually
fails to meet any such commitment. If Caliper delivers such termination notice
to HP, HP may cure by meeting the required HP Operating Expense commitment
within [ * ] of such notice.

(b) If the Collaboration is terminated pursuant to Section 10.5(a),
all of the terms under Section 10.4 will apply, except that:

(i) HP shall not have a license under Caliper Technology to
develop, manufacture or sell New Products; and

(ii) With regard to Collaboration Products,

(1) Caliper shall have the right to contract with any
company, including [ * ], at any time;

(2) Caliper may cease taking supply from HP for some or all
of Caliper's Instrument requirements before the end of the [ * ] year period
described in Section 10.4(c);

(3) Caliper may elect to continue to supply HP's requirements
for LabChips [ * ] for longer than the [ * ] year period described in Section
10.4(c). Caliper will not be required to train HP in LabChip manufacture as
provided in Section 10.4(e), and HP will not have rights to manufacture
LabChips, unless and until Caliper notifies HP that it intends to cease
supplying HP's requirements for LabChips. Any such notice must be delivered at
least [ * ] months in advance of ceasing supply; and

(4) HP shall continue to make Gross Margin share payments to
Caliper on all Collaboration Products at the rates applicable during the
Collaboration [ * ]. These payments will be made on the same schedule and terms
as during the Collaboration under Article 7.

11. INDEMNIFICATION AND LIMITATION OF LIABILITY

11.1 INDEMNIFICATION BY CALIPER. Caliper shall indemnify HP, its
Affiliates, and all their officers, directors, employees and agents, for any
reasonable out-of-pocket costs and expenses (including court and arbitration
costs and reasonable attorneys' fees), non-appealed or non-appealable judicial
or arbitration damage awards, and settlement payments, payable or owed by HP in
connection with any demands, law suits and other legal actions by Third Parties
("Third Party Claim") against HP arising from any negligent actions or willful
misconduct by Caliper, its Affiliates, agents or sublicensees.

11.2 INDEMNIFICATION UNDERTAKING BY HP. HP shall indemnify Caliper,
its Affiliates and sublicensees, and all their officers, directors, employees
and agents, for any reasonable out-of-pocket costs and expenses (including court
and arbitration costs and reasonable attorneys'

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

34
35

fees), non-appealed or non-appealable judicial or arbitration damage awards, and
settlement payments agreed with the Third Party claimants payable or owed by
Caliper in connection with any Third Party Claim against Caliper arising from
any negligent actions or willful misconduct by HP, its Affiliates, or agents.

11.3 CONDITIONS AND LIMITATIONS OF INDEMNIFICATION OBLIGATION.

(a) In order to maintain the right to be indemnified by the other
party ("Indemnitor"), the party claiming indemnification ("Indemnitee") must:

(i) notify the Indemnitor promptly after learning of a Third
Party Claim;

(ii) allow the Indemnitor to manage and control (by way of
intervention or otherwise) the defense and settlement of any such Third Party
Claim against the Indemnitee;

(iii) cooperate with the Indemnitor in the defense or the
settlement negotiations of Third Party Claims as reasonable required by the
Indemnitor; and

(iv) abstain from making any statements or taking any actions
which damage the defense against a Third Party Claim (including, without
limitation, any statements against the interest of the Indemnitee or admissions
of causation or guilt).

(b) The Indemnitor shall not agree to any settlement that
adversely affects the Indemnitee's rights or interest without the Indemnitee's
prior written approval (which approval shall not be unreasonably withheld).

(c) The Indemnitor shall have no obligation to indemnify the
Indemnitee to the extent that a Third Party Claim results from the negligence or
willful misconduct of the Indemnitee.

11.4 LIMITATION OF LIABILITY. Subject to the indemnification
obligation set forth above and unless otherwise expressly stated in this
Agreement, neither party will be liable to the other for any indirect,
consequential, special, or punitive damages regardless of whether such damages
are based on tort, warranty, contract or any other legal theory, even if advised
of the possibility of such damages.

12. GOVERNING LAW; DISPUTE RESOLUTION

12.1 GOVERNING LAW. This Agreement shall be governed by California
law, excluding its choice of law rules.

12.2 DISPUTE RESOLUTION

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

35
36

(a) RISK OF FAILURE. The parties recognize that risk is inherent
in development efforts such as those being undertaken in this collaboration.
Both parties voluntarily assume this risk. Accordingly, a failure of any HP
Technology, Caliper Technology or Collaboration Product developed under this
Agreement to perform as desired despite the reasonable efforts of the
responsible party or parties will not be deemed to be a breach of this
Agreement.

(b) NOTICE OF DISPUTE.

(i) If a purported breach has not been cured to the
satisfaction of both parties within the cure period, either party may give
notice to the other that there is a Dispute between them specifying the matter
in dispute. The Dispute will be resolved according to the Dispute Resolution
Procedure set forth in this Section 12.

(ii) The parties recognize that disagreements may occur
between them in the absence of any breach. If such a disagreement occurs
respecting the parties' rights and obligations under this Agreement, the parties
will meet and confer at the working level in a reasonable attempt to resolve the
disagreement. If the parties are unable to resolve the disagreement at the
working level, either may give notice to the other that there is a Dispute
between them specifying the matter in dispute. The Dispute will be resolved
according to the Dispute Resolution Procedure set forth in this Section 12.

(i) Within thirty days after receipt of a notice of Dispute,
the Executive Sponsors will meet and confer using reasonable efforts to resolve
the Dispute. If they are unable to resolve the Dispute within thirty days,
either party may give notice of escalation to the other that the Dispute is
being escalated to the Senior Executive level.

(ii) Within thirty days after delivery of the notice of
escalation, each party will designate a Senior Executive having the rank of Vice
President or higher. The Senior Executives of the parties will meet and engage
in good faith efforts to resolve the Dispute.

(iii) If the Senior Executives are unable to resolve the
Dispute within thirty days, either party may by notice to the other request a
conference to determine a procedure for resolving the Dispute. Within thirty
days after delivery of the notice, the parties will meet and confer using
reasonable efforts to determine a mutually agreeable procedure for resolving the
Dispute, taking into consideration the relative advantages, disadvantages and
costs of such procedures as mediation, arbitration, mini-trials, or other
alternative dispute resolution mechanisms. The parties will have thirty days to
agree on a procedure for resolving the Dispute.

(iv) No other remedy may be sought by either party until all
the steps of this Dispute Resolution Procedure have first been used. Neither
party may bring an action in a court of law against the other respecting any
issue arising under this Agreement unless the issue has been the subject of a
Dispute and the parties have been unable to resolve such Dispute even after
following all the steps of the Dispute Resolution Procedure set forth above.
Neither party may refuse to perform its obligations under this Agreement because
of any breach purportedly

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

36
37

committed by the other unless the purported breach has been the subject of a
Dispute and parties have been unable to resolve such dispute even after
following all the steps of the Dispute Resolution Procedure.

(v) Any applicable statute of limitations will be tolled
during the Dispute Resolution Procedure.

13. MISCELLANEOUS

13.1 EFFECTS OF BANKRUPTCY. The parties understand and agree that the
rights and licenses granted under or pursuant to this Agreement by one party to
the other are, for all purposes of Section 365(n) of Title 11 of the United
States Code, licenses of rights to "intellectual property" as defined in Title
11, and that each party, as licensee of such rights under this Agreement shall
retain and may fully exercise all of its rights and elections under Title 11.

13.2 FORCE MAJEURE. Neither party shall lose any rights hereunder or
be liable to the other party for damages or losses on account of failure of
performance by the defaulting party if the failure is occasioned by government
action, war, fire, earthquake, explosion, flood, strike, lockout, embargo, act
of God, or any other similar or dissimilar cause beyond the control of the
defaulting party, provided that the party claiming force majeure has exerted all
reasonable efforts to avoid or remedy such force majeure.

13.3 NO RECRUITING. Neither party shall solicit or seek to employ any
person who is an employee of the other party during the term of this Agreement
and for one (1) year thereafter. However, this clause does not prevent either
party from engaging in recruiting activities directed to the community at large
and not targeted specifically at employees of the other, even if such activities
result in recruiting an employee of the other. This shall not preclude either
party from receiving and accepting unsolicited applications from such employees.

13.4 ASSIGNMENT.

(a) Except as expressly permitted by this Agreement, neither
party may assign any of its rights or obligations under this Agreement to a
Third Party except in connection with a merger, acquisition or similar
reorganization or the sale of all or substantially all of its assets, or
otherwise with the prior written consent of the other party. This Agreement
shall survive any such merger, acquisition or reorganization of either party
with or into, or such sale of assets to, another party and no consent for such
merger, acquisition, reorganization or sale shall be required hereunder;
provided, that in the event of such merger, acquisition, reorganization or sale,
no intellectual property rights of the acquiring corporation shall be included
in the technology licensed hereunder. With regard to HP, this Section shall
refer to HP's Chemical Analysis Group and not the mother ship.

(b) This Agreement shall be binding upon and inure to the benefit
of the successors and permitted assigns of the parties. Any assignment not in
accordance with this Agreement shall be void.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

37
38

13.5 SEVERABILITY. If any term, condition or provision of this
Agreement is held to be unenforceable for any reason, it shall, if possible, be
interpreted rather than voided, in order to achieve the intent of the parties to
this Agreement to the extent possible. In any event, all other terms, conditions
and provisions of this Agreement shall be deemed valid and enforceable to the
full extent.

13.6 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be an original and all of which shall
constitute together the same document.

13.7 ENTIRE AGREEMENT; AMENDMENTS IN WRITING. This Agreement and the
Stock Purchase Agreement described in Section 7.1 together comprise the entire
understanding between the parties with respect to their subject matter and
supersede any previous communications, representations, or agreements, whether
oral or written, including without limitation the Draft Outline of Principal
Terms dated March 5, 1998. All information heretofore exchanged between the
parties pursuant to the Confidentiality Agreement heretofore entered into
between the parties will henceforth be subject to the applicable provisions of
this Agreement. For purposes of construction, this Agreement will be deemed to
have been drafted by both parties. No modification of this Agreement will be
binding on either party unless in writing and signed by an authorized
representative of each party.

13.8 NOTICE. Any notice or other communication required or permitted
to be given to either party hereto shall be in writing and shall be deemed to
have been properly given and to be effective on the date of delivery if
delivered in person, by facsimile or by nationally recognized express courier,
or effective fourteen (14) days after mailing by U.S. Postal Service, postage
prepaid, as Registered or Express Mail, postage paid, to the other party at the
following address:

Caliper: Caliper Technologies Corp. with copy to:
0000 Xxxxxxxxxx Xxxxxx Cooley Godward LLP
Xxxx Xxxx XX 00000 Five Palo Alto Square
Attention: Chief Executive Officer 0000 Xx Xxxxxx Xxxx
Xxxx Xxxx, XX 00000
Fax: (000) 000-0000
Attn: Xxxxx X. Xxxxxxxxxx

HP: Hewlett-Packard GmbH with copy to:
Waldbronn Analytical Division Hewlett-Packard Company
Xxxxxxx-Xxxxxxx Xxxxxxx 0 Office of General Counsel
76337 Waldbronn 0000 Xxxxxxx Xxxxxx
Xxxxxxx Xxxx Xxxx XX 00000
Attention: General Manager

Either party may change its address for communications by a notice to
the other party in accordance with this section.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

38
39

IN WITNESS WHEREOF, the parties have executed this Agreement as of
the date first set forth above.

CALIPER TECHNOLOGIES CORP. HEWLETT PACKARD COMPANY

By: /s/ Xxxxxx Xxxx By: /s/ Xxxx X. Xxxxxxx
----------------------------------- ----------------------------
Xxxxxx Xxxx, Chief Operating Officer Xxxx Xxxxxxx, Controller
Chemical Analysis Group

By: /s/ X. Xxxxxxxx
----------------------------
Xxxxxxxxx Xxxxxxxx,
General Manager
Waldbronn Analytical Division

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

39
40

EXHIBIT A

LAB ON A CHIP TECHNOLOGY

General Description: see "Definitions" section of Agreement

The following are examples of what's included in the above-referenced
definition:

[ * ]

The following are examples of what's not included in the above-referenced
definition:

[ * ]

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

40
41

EXHIBIT B

Outline of selected terms of OEM Agreement

The parties agree to use reasonable business efforts to execute a formal OEM
agreement [ * ] including the following terms:

1. A [ * ] rolling forecast using reasonable forecasting processes.

2. Orders will become firm [ * ] prior to scheduled delivery.

3. A [ * ] target supply response time (SRT).

4. Caliper will use reasonable business efforts to maintain stable target SRT
and if greater than [ * ] then the parties agree to meet and agree on a
correction plan. If the SRT is greater than [ * ], then Caliper agrees to
enable HP to manufacture chips. However, this clause will not become
effective until after the [ * ].

5. The parties will mutually agree to the [ * ] and will use reasonable business
efforts to accelerate such date.

6. Caliper will not make engineering changes after the manufacturing release of
a product without notification of HP.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

Document Metadata

Table of Contents

EXHIBIT 10.10 COLLABORATION AGREEMENT THIS COLLABORATION AGREEMENT (the "Agreement") is entered into as of May 2, 1998 (the "Effective Date"), by and between CALIPER TECHNOLOGIES CORP., a corporation organized under the laws of the State of Delaware...

Document Metadata